GlassScriptPhysician profile
Alyssa B Sapp
NPI 1710130802
$915.35
in general payments reported to CMS, 2019-2025
16 companies · $151 in 2025
The $151 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $273 · 2022: $162 · 2023: $143 · 2024: $187 · 2025: $151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $481.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $480.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $243.45 | 2021-2025 | |
| Kaleo, INC. | $169.63 | 2021-2023 | Auvi-Q |
| Grifols USA, LLC | $132.42 | 2023-2024 | Xembify, Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $111.46 | 2022-2024 | Dupixent |
| Novartis Pharmaceuticals Corporation | $34.38 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.96 | 2024-2025 | Takhzyro |
| Teva Pharmaceuticals USA, INC. | $28.24 | 2022 | |
| Sanofi-Aventis U.S. LLC | $20.18 | 2021 | |
| Genentech USA, INC. | $19.92 | 2025 | Xolair |
| Ars Pharmaceuticals Operations, INC. | $19.33 | 2025 | Neffy |
| Pharming Healthcare, INC. | $19.33 | 2024 | Ruconest |
| Ionis Pharmaceuticals, INC. | $18.75 | 2025 | Dawnzera |
| Optinose US, INC. | $18.02 | 2021 | |
| Alk-Abello, INC | $16.63 | 2021 | |
| Lilly USA, LLC | $16.58 | 2025 | Ebglyss |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $14.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alyssa Sapp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.